Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.

Abstract

Idecabtagene vicleucel (ide-cel, bb2121), a chimeric antigen receptor (CAR) T cell therapy, has been investigated in patients with relapsed and refractory multiple myeloma (RRMM) who have received an immunomodulatory drug, proteasome inhibitor, and anti-CD38 antibody in the single-arm phase 2 KarMMa clinical trial. Two therapies with distinct mechanisms of action - selinexor plus dexamethasone (Sd) and belantamab mafodotin (BM) - are currently approved in the United States for heavily pretreated patients, including those who are triple-class refractory. To compare ide-cel versus Sd and ide-cel versus BM, matching-adjusted indirect comparisons were performed. Ide-cel extended progression-free survival (PFS) and overall survival (OS) versus both Sd and BM (hazard ratio (HR); 95% confidence interval (CI)). PFS: ide-cel versus Sd, 0.46; 0.28-0.75; ide-cel versus BM, 0.45; 0.27-0.77. OS: ide-cel versus Sd, 0.23; 0.13-0.42; ide-cel versus BM, 0.35; 0.14-0.87. These results suggest ide-cel offers clinically meaningful improvements over currently approved regimens for patients with heavily pretreated RRMM.

• Authors: Paula Rodriguez-Otero, Dieter Ayers, Shannon Cope, Faith E Davies, Michel Delforge, Ali Mojebi, Jeroen P Jansen, Katja Weisel, Kristen Hege, Sujith Dhanasiri
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 10 Pg. 2482-2491 (10 2021) ISSN: 1029-2403 [Electronic] United States
• PMID: 33896344 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Hydrazines
• Triazoles
• selinexor
• Dexamethasone
• belantamab mafodotin

Topics

• Antibodies, Monoclonal, Humanized
• Dexamethasone
• Humans
• Hydrazines
• Multiple Myeloma (drug therapy)
• Triazoles
• United States